Fortis Healthcare (FORTIS)₹774.55+0.12%Hospital
In the Jun 2026 quarter (consolidated), Fortis Healthcare reported sales of ₹2,553 Cr, up 17.5% from Jun 2025, and net profit of ₹273 Cr, up 2.3% year on year. For the year to Mar 2026, sales were ₹9,160 Cr and net profit ₹1,065 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,777 | 1,687 | 1,791 | 1,866 | 1,996 | 1,935 | 2,014 | 2,173 | 2,339 | 2,273 | 2,373 | 2,553 |
| Expenses | 1,437 | 1,395 | 1,402 | 1,513 | 1,551 | 1,551 | 1,569 | 1,674 | 1,773 | 1,755 | 1,829 | 2,003 |
| Operating Profit | 330 | 284 | 381 | 343 | 435 | 375 | 435 | 491 | 556 | 506 | 532 | 537 |
| OPM % | 19.0% | 17.0% | 21.0% | 18.0% | 22.0% | 19.0% | 22.0% | 23.0% | 24.0% | 22.0% | 23.0% | 21.0% |
| Other Income | 17.98 | 18.99 | 16.98 | 13.98 | −41.96 | 46.93 | −28.98 | 30.95 | 49.99 | −33.95 | −1.99 | 27.97 |
| Interest | 32.04 | 33.01 | 35.04 | 35.03 | 36.04 | 45.07 | 68.02 | 70.10 | 75.05 | 86.04 | 84.11 | 80.04 |
| Depreciation | 84.11 | 87.01 | 92.01 | 91.10 | 95.13 | 97.09 | 102 | 101 | 106 | 120 | 122 | 122 |
| Profit before tax | 232 | 183 | 270 | 229 | 260 | 278 | 236 | 350 | 424 | 265 | 323 | 362 |
| Tax % | 21.0% | 27.0% | 25.0% | 24.0% | 26.0% | 9.0% | 21.0% | 24.0% | 23.0% | 26.0% | 16.0% | 25.0% |
| Exceptional items | 3.01 | 6.01 | 2.01 | 0.00 | −44.06 | 22.05 | −43.11 | 10.02 | 18.04 | −34.08 | −10.01 | 7.01 |
| Net Profit | 184 | 134 | 203 | 174 | 193 | 254 | 188 | 267 | 329 | 197 | 271 | 273 |
| EPS (Rs) | 2.31 | 1.79 | 2.38 | 2.21 | 2.35 | 3.29 | 2.45 | 3.46 | 4.27 | 2.58 | 3.53 | 3.54 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4,218 | 4,594 | 4,580 | 4,484 | 4,647 | 4,044 | 5,738 | 6,321 | 6,914 | 7,809 | 9,160 | 9,538 |
| Expenses | 4,102 | 4,212 | 4,279 | 4,230 | 4,016 | 3,620 | 4,640 | 5,190 | 5,614 | 6,182 | 7,033 | 7,361 |
| Operating Profit | 92.05 | 354 | 274 | 231 | 610 | 404 | 1,069 | 1,101 | 1,268 | 1,589 | 2,085 | 2,131 |
| OPM % | 2.2% | 8.0% | 6.0% | 5.0% | 13.0% | 10.0% | 19.0% | 17.0% | 18.0% | 20.0% | 23.0% | 22.3% |
| Other Income | 299 | 648 | −689 | 228 | 126 | 94.83 | 367 | 157 | 63.91 | −10.99 | 44.94 | 42.02 |
| Interest | 133 | 229 | 258 | 337 | 205 | 166 | 147 | 129 | 131 | 184 | 314 | 325 |
| Depreciation | 225 | 222 | 239 | 233 | 292 | 291 | 301 | 316 | 342 | 386 | 450 | 471 |
| Profit before tax | 33.87 | 550 | −909 | −110 | 238 | 42.85 | 985 | 812 | 856 | 1,004 | 1,361 | 1,374 |
| Tax % | −24.0% | 13.0% | 2.0% | 103.0% | 62.0% | 230.0% | 20.0% | 22.0% | 25.0% | 20.0% | 22.0% | — |
| Exceptional items | 20.02 | −2.01 | −794 | −75.10 | −1.01 | −4.01 | 256 | 72.10 | 15.03 | −69.17 | −15.02 | −19.04 |
| Net Profit | 42.02 | 480 | −936 | −224 | 91.17 | −56.07 | 791 | 634 | 645 | 810 | 1,065 | 1,071 |
| EPS (Rs) | 0.41 | 8.16 | −19.49 | −3.97 | 0.78 | −1.46 | 7.36 | 7.81 | 7.94 | 10.29 | 13.83 | 13.92 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 12.9% | 12.9% | 10.0% | 7.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 464 | 464 | 519 | 520 | 757 | 758 | 758 | 757 | 757 | 757 | 758 | 758 |
| Reserves | 3,592 | 4,006 | 4,635 | 3,550 | 5,856 | 5,919 | 5,377 | 5,432 | 6,501 | 6,920 | 8,180 | 9,165 |
| Borrowings | 1,784 | 1,511 | 2,217 | 1,960 | 2,008 | 1,594 | 1,532 | 1,254 | 926 | 1,154 | 2,477 | 3,475 |
| Other Liabilities | 1,768 | 1,263 | 2,238 | 2,467 | 2,889 | 2,794 | 3,231 | 4,102 | 3,940 | 4,173 | 1,995 | 2,477 |
| Total Liabilities | 7,610 | 7,245 | 9,609 | 8,498 | 11,510 | 11,065 | 10,897 | 11,546 | 12,124 | 13,004 | 13,409 | 15,873 |
| Fixed Assets | 4,235 | 3,656 | 5,439 | 5,008 | 8,502 | 8,832 | 8,831 | 9,446 | 9,461 | 9,909 | 10,457 | 12,270 |
| CWIP | 228 | 226 | 268 | 226 | 450 | 204 | 165 | 193 | 228 | 543 | 407 | 435 |
| Investments | 1,464 | 1,453 | 1,880 | 1,734 | 270 | 175 | 186 | 104 | 210 | 230 | 169 | 243 |
| Other Assets | 1,682 | 1,912 | 2,022 | 1,529 | 2,289 | 1,854 | 1,715 | 1,802 | 2,224 | 2,323 | 2,377 | 2,926 |
| Inventories | 63.78 | 59.77 | 61.71 | 66.75 | 56.73 | 77.70 | 76.71 | 123 | 122 | 107 | 114 | 134 |
| Trade receivables | 410 | 445 | 474 | 472 | 544 | 460 | 459 | 514 | 584 | 630 | 786 | 1,046 |
| Cash & equivalents | 189 | 166 | 544 | 219 | 852 | 265 | 415 | 412 | 362 | 596 | 506 | 542 |
| Total Assets | 7,610 | 7,245 | 9,609 | 8,498 | 11,510 | 11,065 | 10,897 | 11,546 | 12,124 | 13,004 | 13,409 | 15,873 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 24.07 | 196 | 969 | 495 | −179 | 173 | 487 | 868 | 824 | 1,103 | 1,429 | 1,605 |
| Cash from investing activity | 212 | 122 | −999 | −332 | −3,269 | 62.88 | −131 | −500 | −371 | −886 | −778 | −1,534 |
| Cash from financing activity | −305 | −355 | 260 | −673 | 4,266 | −864 | −143 | −518 | −472 | −86.18 | −716 | 164 |
| Net cash flow | −66.04 | −37.01 | 225 | −513 | 799 | −627 | 212 | −153 | −21.01 | 125 | −69.99 | 228 |
| Capex | 243 | 230 | 278 | 180 | 82.99 | 156 | 219 | 215 | 461 | 942 | 848 | 946 |
| Free cash flow | −181 | −162 | 691 | 438 | −262 | 35.05 | 275 | 752 | 368 | 172 | 592 | 674 |
| CFO / OP % | 130.9% | 353.9% | 303.9% | 186.9% | 29.9% | 84.0% | 107.9% | 101.0% | 99.9% | 103.9% | 96.9% | 89.9% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 37 | 38 | 37 | 37 | 43 | 35 | 40 | 32 | 33 | 32 | 36 | 41 |
| Inventory days | 25 | 23 | 23 | 24 | 22 | 30 | 29 | 33 | 31 | 24 | 23 | 24 |
| Days payable | 207 | 218 | 215 | 279 | 296 | 226 | 205 | 178 | 179 | 164 | 161 | 165 |
| Cash conversion cycle | −143 | −155 | −154 | −216 | −229 | −160 | −134 | −111 | −114 | −106 | −100 | −98 |
| Working capital days | −70 | −68 | −86 | −112 | −233 | −149 | −55 | −34 | −21 | −123 | −29 | −33 |
| ROCE % | 0.0% | 3.0% | 10.9% | 3.0% | 6.0% | 4.0% | 2.0% | 9.9% | 10.0% | 10.0% | 12.0% | 12.9% |
For the Jun 2026 quarter, Fortis Healthcare reported sales of ₹2,553 Cr, up 17.5% year on year and net profit of ₹273 Cr, up 2.3% year on year. The operating margin was 21.0%.
Fortis Healthcare's sales for the year to Mar 2026 were ₹9,160 Cr; over the last twelve months they were ₹9,538 Cr.
Net profit for the year to Mar 2026 was ₹1,065 Cr, and ₹1,071 Cr over the last twelve months. Earnings per share over the same trailing period were ₹13.92.
Fortis Healthcare reported borrowings of ₹3,475 Cr at Mar 2026, against cash and equivalents of ₹542 Cr.
Cash from operations was ₹1,605 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹674 Cr.